Article:Plasma-free amino acid profiles are predictors of cancer and diabetes development. (5380892)

From ScienceSource
Jump to: navigation, search

This page is the ScienceSource HTML version of the scholarly article described at Its title is Plasma-free amino acid profiles are predictors of cancer and diabetes development. and the publication date was 2017-03-13. The initial author is X Bi.

Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.

Converted JATS paper:

Journal Information

Title: Nutrition & Diabetes

Plasma-free amino acid profiles are predictors of cancer and diabetes development

Alternative Title: Plasma-free amino acid profiles

  • X Bi
  • C J Henry

Publication date (ppub): 03/2017

Publication date (epub): 03/2017

Publication date (pmc-release): 3/2017


Type 2 diabetes (T2D) and cancers are two major causes of morbidity and mortality worldwide. Nowadays, there is convincing evidence of positive associations between T2D and the incidence or prognosis of a wide spectrum of cancers, for example, breast, colon, liver and pancreas. Many observational studies suggest that certain medications used to treat hyperglycemia (or T2D) may affect cancer cells directly or indirectly. The potential mechanisms of the direct T2D cancer links have been hypothesized to be hyperinsulinemia, hyperglycemia and chronic inflammation; however, the metabolic pathways that lead to T2D and cancers still remain elusive. Plasma-free amino acid (PFAA) profiles have been highlighted in their associations with the risks of developing T2D and cancers in individuals with different ethnic groups and degree of obesity. The alterations of PFAAs might be predominately caused by the metabolic shift resulted from insulin resistance. The underlying mechanisms have not been fully elucidated, in particular whether the amino acids are contributing to these diseases development in a causal manner. This review addresses the molecular and clinical associations between PFAA alterations and both T2D and cancers, and interprets possible mechanisms involved. Revealing these interactions and mechanisms may improve our understanding of the complex pathogenesis of diabetes and cancers and improve their treatment strategies.



Diabetes mellitus (DM) and cancer are two severe chronic diseases with tremendous impact on global health. Epidemiologic studies have shown that several forms of cancers, such as liver, pancreas, endometrium, colorectal, breast and bladder, develop more frequently in patients with diabetes.[1], [2] Diabetes (primarily type 2, T2D) and cancers share many common risk factors, for example, aging, physical inactivity, diet and obesity. The potential biologic links between these two diseases are yet incompletely understood but may involve insulin resistance.[3]

Insulin resistance, intertwined with hyperinsulinemia, has been suggested as one of the possible underlying mechanisms for the direct connection between T2D and cancers.[3] T2D is typically preceded by hyperinsulinemia to maintain glucose homeostasis.[4] Additionally, convincing evidence have suggested that hyperinsulinemia may affect the signaling pathways of insulin and insulin-like growth factor 1 (IGF-1) and thus facilitate cancer development and progression.[5] The etiology of insulin resistance has been either focused on lipid-mediated mechanisms[6] or the interplay with obesity, which induces metabolic abnormalities.[7] The latter is partly reflected in the abnormal circulating levels of lipid, protein and other classes of metabolites. Among the numerous metabolites, amino acids may have potential as excellent disease biomarkers because they are involved in protein synthesis and as metabolic regulators.[8] In 1969, hyperaminoacidemia, manifested by elevated plasma-free amino acids (PFAAs) including branched-chain amino acids (BCAAs), that is, valine (Val), leucine (Leu), isoleucine (Ile) and aromatic amino acids (AAAs), that is, tyrosine (Tyr) and phenylalanine (Phe) in obese subjects, was reported.[9] Hyperaminoacidemia in obesity may be a manifestation of increased insulin resistance.

Insulin has long been recognized as the regulator of branched-chain alpha-keto acid dehydrogenase complex, an enzyme complex involved in BCAA catabolism.[10] Insulin resistance has been found to reduce the enzymatic activity of branched-chain alpha-keto acid dehydrogenase complex and hence suppress BCAA catabolism. This is considered as the plausible etiology of increased BCAA levels in obesity and/or diabetes.[11] Indeed, evidence is accumulating that there is positive association between insulin resistance and circulating concentrations of BCAAs.[12], [13], [14], [15] In addition, insulin resistance was shown to be correlated with the alterations of several other PFAAs, including AAAs, alanine (Ala), proline (Pro) and glycine (Gly).[16]

In recent years, PFAA profiles were found to be significantly altered in patients with diabetes and/or cancers.[17], [18], [19], [20], [21] Little is known about the mechanisms, particularly whether PFAAs are contributing to the development of these diseases in a causal manner. However, the altered PFAA profiling appears to provide a great diagnostic potential and could be a promising biomarker for understanding the etiology and pathogenesis of diabetes and cancers.[22]

Altered PFAA profiles in cancer patients

Cancer cells require certain amino acids, for example, glutamine (Gln), Gly, aspartic acid (Asp) and serine (Ser), for DNA synthesis, building new blood vessels, and duplicating their entire protein contents.[23] They also require amino acids for proteins synthesis. These proteins work as growth-promoting hormones or tumor growth factors.[24], [25] The increase in the amino acid demand may thus lead to a lower availability of PFAAs in cancer patients.[26]Table 1 summarizes twenty studies specifically addressed the alterations of circulating amino acid concentrations in different cancer patients.

Vissers et al.[27] analyzed the PFAA concentrations in three types of cancer patients with different levels of weight loss, that is, breast cancer (without weight loss), colonic cancer (occasional weight loss) and pancreatic cancer (frequent weight loss). They found a significant decrease in arginine (Arg) levels, regardless of tumor types and stages, weight loss or body mass index. This finding suggested that decreased Arg availability was a specific feature of the presence of a malignant tumor. They also revealed that BCAA concentrations were lower in all cancer patients than in age- and sex-matched controls; whereas TAAs were lower only in pancreatic cancer patients. It should be noted that the alterations of PFAA levels depend on the stage and the type of cancers. The study conducted by Gu et al.[28] examined the PFAA profiles in 56 patients with gastric cancer, 28 patients with breast cancer, 33 patients with thyroid cancer and 137 healthy controls which were age matched. It was found that histidine (His) level was significantly decreased in breast cancer patients. Levels of Ser, Ala, Val, lysine (Lys), His, BCAAs, and TAAs were significantly decreased in gastric cancer patients. However, the thyroid cancer patients had significantly increased levels of methionine (Met), Leu, Tyr and Lys (Table 1). Besides the different types of cancers, the variation of PFAA pattern of patients was due to the different disease stages. Most of the patients with breast cancer or thyroid cancer in this study were characterized as early stage, whereas 12 of gastric cancer patients were characterized as advanced stage (stage IV). This study also showed that Ala, Arg, Asp and cysteine (Cys) promoted the proliferation of breast cancer cells. Alternatively, Cys promoted the proliferation of gastric cancer cells, but Ala and glutamic acid (Glu) inhibited it. These results underscored the potential function of the assessment of tumor-related PFAA patterns to examine and diagnose various cancers.

Recently, AminoIndex Cancer Screening (AICS) technology was employed as a novel cancer risk calculation method for early stage cancer diagnosis.[21], [29], [30], [45], [46] In order to build AICS, 19 amino acids including threonine (Thr), asparagine (Asn), Ser, Gln, Pro, Gly, Ala, citrulline (Cit), Val, Met, Ile, Leu, Tyr, Phe, His, tryptophan (Trp), ornithine (Orn), Lys and Arg, were measured and statistically analyzed. For the colorectal cancer risk calculation in one case report,[21] plasma levels of Ser, Pro, Val, Met, Ile and Lys were used. The AICS score was found to be 8.3, which indicated that the patient had an ~10-fold-increased risk of cancer. When the patient underwent colonscopy, a 10-mm adenoma-like lesion in the ascending colon with partial carcinoma was observed. The early detection of carcinoma using AICS method allowed complete resection, suggesting that PFAA profiles may provide a fast and easy diagnostic tool for cancers. Another study conducted by Fukutake et al.[20] used Ser, Asp, Ile, Ala, His and Trp as variables to calculate the pancreatic cancer risk and successfully discriminate patients with pancreatic cancer (n=360) from control subjects (n=8372). They also analyzed the levels of 19 amino acids and a significant increase in Ser level and significant decreases in the levels of Thr, Asn, Pro, Ala, Cit, Val, Met, Leu, Tyr, Phe, His, Trp, Lys and Arg were observed in pancreatic cancer patients. Several other studies with small sample size[37], [38] reported similar decreases in circulating amino acid levels in pancreatic cancer patients, which was interpreted as a result of the enhanced usage of PFAAs in tumors. Another possibility for the decreased levels of amino acids was associated with malnutrition. Patients with pancreatic cancer are usually troubled by malnutrition due to exocrine pancreatic insufficiency (EPI).

However, some studies investigating amino acid levels in plasma or serum samples from patients with breast cancer showed contradictory results (Table 1). Poschke et al.[31] reported increased levels of Glu, Ser, Gln, Ala, Val, Phe, Ile and Leu in 41 breast cancer patients. One possible explanation could be that the stage of tumor in this study population was categorized as early stage such that it did not reduce the amino acid pool. The increased level of Ser was probably due to the increased enzymatic activity involved in Ser biosynthesis in tumor cells.[47] The increased levels of Glu and Ala may be produced by tumor cells.[48] Similar increment of amino acid levels, that is, Orn, Glu and Trp in breast cancer patients, was observed previously.[49] However, other study demonstrated a decrease of Gln, Tyr, Phe, His and Trp, whereas an increase of Thr, Ser, Pro, Gly, Ala, Orn and Lys, in 196 patients with breast cancer.[29] The above mentioned contradictory results might be attributed to the differences in participant characteristics, including age, gender, ethnic background, diet, and countries where participants live, different measurement techniques applied for PFAA profiles, different diseases stage, and lack of data adjustment for potential confounders. Meanwhile, PFAA profiles may be affected by various factors, including the amount and/or composition of dietary protein, metabolism of muscle protein, as well as the labile protein reserve in different tissues.

Mechanism underlying alterations of PFAA profiles

Table 1 shows that patients with cancers have altered PFAA profiles. Apparently, the pattern and degree of the alterations depend on the type of cancer and the disease stage. Determination of the precise mechanism underlying changes in the PFAA profiles has the great potential for cancer diagnosis and treatment. Various recent studies tried to find out the connections between cancers and specific PFAA profiles (Table 2). Among all of the amino acids, Gln has attracted great attentions as cancer cells are known to be avid consumers of Gln.[50], [51] Building on the Warburg effect,[52] cancer cells extensively use Gln to produce ATP (adenosine-triphosphate) to sustain anabolism, which is necessary for tumor growth and proliferation. It has been demonstrated that breast cancer cell lines expressing high levels of c-MYC were dependent on Gln for their survival and growth.[53] As shown in Table 1, significant decrease of Gln was observed in patients with pancreatic cancer,[27], [38] Lung cancer, gastric cancer, colorectal cancer, breast cancer and prostate cancer.[29] On the other hand, the increased Glu levels in colorectal cancer patients[30] and breast cancer patients[30], [31], [32] could also be interpreted as the result of increased Gln metabolism in tumor cells. Although Gln consumption is increased in most tumors, some cancer cells can survive and proliferate by relying on glucose without Gln.[54]

Gly and Ser are biosynthetically linked, both of which are classic metabolites of glycolysis. The biosynthesis pathway of Ser utilizes the glycolysis intermediate 3-phosphoglycerate, which is converted by phosphoglycerate dehydrogenase, phosphoserine aminotransferase and phosphoserine phosphatise into Ser. In Gly metabolism, Gly is converted to methylenetetrahydrofolate by glycine decarboxylase. Meanwhile, serine hydroxymethyltransferase converts Ser to Gly reversibly, linking the respective pathways of metabolism. Jain et al.[55] reported that Gly biosynthetic pathway was closely linked to cancer cell proliferation. A significant correlation between Gly consumption and cancer cell proliferation was observed, suggesting that Gly uptake and catabolism was able to promote tumourigenesis and malignancy. Additionally, emerging evidence suggested that aberrant activation of the biosynthetic pathway of Ser was an essential process in cancer pathogenesis.[56] According to previous studies, glycine decarboxylase is highly expressed in several human cancers, including ovarian cancer,[55] non-small-cell lung carcinoma[57] and breast cancer.[58] Phosphoglycerate dehydrogenase (the key enzyme for Ser biosynthesis) expression is normally upregulated in breast cancer and melanoma.[59] As summarized in Table 1, Gly consumption was pronounced in pancreatic cancer,[27] breast cancer,[28], [29] colorectal cancer[41] and cervical cancer.[42] While Ser levels were high in some patients with pancreatic cancer,[20] breast cancer,[31], [32] lung cancer, and colorectal cancer,[29] probably due to the overexpression of phosphoglycerate dehydrogenase, other cancers, such as colorectal cancer,[21], [27], [42] pancreatic cancer,[27] gastric cancer[28] and cervical cancer[43] consumed Ser. Although Ser and Gly could be inter-converted and either of them might be used for one-carbon metabolism and nucleotide synthesis, convincing evidence suggested that cancer cell proliferation were supported by Ser instead of Gly consumption. Gly was believed to be a consequence of the rapid cell proliferation.[60]

It is well-known that the BCAAs have important roles in the maintenance of lean body mass and regulation of skeletal muscle protein metabolism. Therefore, the investigation of BCAAs and their metabolites in the cancer-bearing state, where muscle wasting is a significant comorbidity, is of importance. Elevated plasma BCAAs levels have been observed to raise the risk of future diagnosis of pancreatic cancer by two-fold.[61] The high BCAA concentrations were attributed to the enhanced whole-body protein breakdown in development of pancreatic ductal adenocarcinoma. Therefore, BCAA profiles could be used as a general marker to diagnose pancreatic ductal adenocarcinoma. In addition, the direct effects of BCAAs on cultured human hepatocellular carcinoma cells have also been reported previously.[62] It was found that increased BCAAs levels suppressed the hepatocellular carcinoma cell lines proliferation. One of the plausible mechanisms underlying suppression of cancer cells by BCAAs was associated with their capability of inhibition of insulin signals through suppressing the expression of IGF.[63] It is believed that insulin induced cell proliferation by activating the mitogen-activated protein kinase pathway.[64] BCAAs have also been reported to accelerate mRNA degradation of insulin-induced vascular endothelial growth factor at the post transcriptional level, downregulating vascular endothelial growth factor expression during the hepatocellular carcinomas development.[65] Furthermore, BCAAs were reported to induce the apoptosis of liver cancer cell lines by inhibiting insulin-induced phosphatidylinositol-3-kinase (PI3K)/Akt and the nuclear factor-kappa beta (NF-κB) signaling pathways through the mammalian target of rapamycin complex 1- (mTORC1) and complex 2- (mTORC2) dependent mechanisms.[66]

Some other amino acids, such as Tau, have been reported to decrease human cervical cancer cell proliferation in a dose- and time-dependent manner.[67] It was also suggested that assessment of serum Tau levels in patients with high breast cancer risk was useful in the early diagnosis of malignant changes in breast.[68] Additionally, plasma Arg levels were lower in patients with cancers, indicating that Arg metabolism may be disturbed in the presence of a malignancy.[27], [44], [69] Although the metabolic changes of different cancers can determine their own unique PFAA profiles, the role of cancer-specific amino acids remains to be elucidated. Further studies are required to verify the significance of PFAA alterations in cancers development and management.

Altered PFAA profiles in diabetes mellitus

T2D is characterized by insulin resistance and/or impaired insulin secretion from beta cells. The prevalence of T2D is markedly increasing around the world and the rates of increase show no signs of slowing.[70] A complete understanding of the pathophysiology of insulin resistance and T2D, or the identification of early stage metabolic alterations, is promising in the study of etiological pathways and may hold the potential to develop preventive strategies. A number of biomarkers, including fasting plasma glucose and glycated hemoglobinA1c, have been proposed as indicators for the estimation of T2D risk.[71] Yet many populations from overweight to moderately obese have completely normal fasting plasma glucose and hemoglobinA1c, leaving them undiagnosed as pre-diabetics in spite of underlying dysfunctional metabolism. This highlights the fact that only considering glucose metabolism was not sufficient when determining the etiology and consequences of T2D.[72]

More and more metabolomics-based studies have consistently reported the perturbation of normal amino acid metabolism in insulin resistance and T2D in recent years.[73] Multiple amino acids, particularly BCAAs, have been shown to be modulators of insulin secretion.[74], [75] Increasing evidence suggests that elevated plasma BCAAs levels may have adverse effects on the regulation of glucose homeostasis, because the oxidation of BCAAs spares glucose utilization in skeletal muscle.[76] On the other hand, for individuals without significant abnormalities in glucose homeostasis, elevations in BCAAs levels, along with AAAs are also significantly associated with an increased future likelihood of developing T2D[77] and cardiovascular diseases.[78] One of the possible mechanisms by which hyperaminoacidemia could promote DM is via hyperinsulinemia leading to pancreatic beta cell exhaustion. The association between insulin resistance and increased circulating BCAAs levels were supported by several other studies with different ethnic groups and degree of obesity.[12], [13], [14], [16], [79], [80]Table 3 summarizes 16 recent studies reporting the associations between PFAA profiles and insulin resistance and T2D.

Shah et al.[13] conducted a large randomized trial to understand health benefits occurring as a result of weight loss by using high-throughput metabolomic profiling. They found that BCAAs were unique to predict the improvement in HOMA-IR (homeostasis model assessment of insulin resistance), and suggested a potential mechanism for the heterogeneity in health benefits obtained from weight loss. The associations between BCAAs concentrations and adverse metabolic profiles were also observed in children and adolescents. It is noteworthy that the elevations in BCAAs may independently predict future insulin resistance in these participants.[14] In the Framingham Offspring Study, BCAAs and AAAs were found to have significant relationships with future development of DM.[77] The combination of three amino acids, that is, Ile, Phe and Tyr, predicted future DM with a four- to six-fold increased risk for participants in top quartile. The combination of Ile, Phe and Tyr also helped to predict future cardiovascular diseases during a long-term follow-up, probably through increased tendency towards the development of atherosclerosis.[78] The plausible etiology of elevated BCAAs levels in obesity is through the suppression of BCAA catabolism by insulin resistance.[11] It should be noted that, besides obesity-associated insulin resistance, BCAAs levels were also positively correlated with HOMA-IR in individuals with normal body mass.[16], [80] The underlying mechanisms between insulin resistance and elevated BCAAs are related with the persistent activations of mTORC and S6K1 as shown in Table 4.

Increased circulating levels of Phe and Tyr (or AAAs) have been reported to be associated with insulin resistant, T2D or cardiovascular diseases states.[77], [78], [79], [80], [82], [84], [87], [88] The directionality of the blood concentration shifts of Phe and Tyr are usually the same because Tyr is the first product of Phe catabolism. In the studies using blood metabolites to predict T2D[77] and determining correlations between metabolites and insulin sensitivity,[89] Phe and Tyr provided some of the strongest associations. The positive correlation between Phe and/or Tyr and insulin secretion may be involved in pathways to compensate early stage of insulin resistance through stimulating insulin secretion (Table 4).

Contrary to BCAAs and AAAs, the relationships of other amino acids with insulin resistance remain incompletely understood. Nakamura et al.[81] recruited 51 of patients with T2D and measured their PFAA profiles. They observed that the levels of Glu, Ala, Trp and BCAAs were inversely correlated with adiponectin concentrations. As adiponectin is very important in the regulation of insulin sensitivity and metabolism, it might be the cause of insulin resistance and change PFAA profiles in diabetic patients. They also found that the concentrations of Ala, Tyr, Glu and Pro were significantly correlated with fasting plasma insulin. There results indicated the strong association between PFAA profiles, circulating adiponectin concentration and insulin resistance; however, the underlying mechanism was unclear. Some other studies in healthy obese[82], [83] and in pre-diabetic subjects[84] suggested that the levels of Ala, Gly, Gln, Glu, Trp, Tyr and BCAAs were correlated with visceral adiposity which was associated with deregulated insulin signaling. However, in the EPIC-Potsdam case–cohort,[85] increased concentration of Phe and reduced concentration of Gly were found to be independently predictive of T2D. Unlike Phe which stimulated insulin secretion, the depletion of Gly may reflect increased gluconeogenesis or glutathione consumption driven by oxidative stress.[90]

Conclusions and future directions

This review has highlighted the potential use of the PFAA profiling as a novel diagnostic tool to access the risk of cancers and T2D. Results from epidemiological studies have suggested that obesity and T2D are positively correlated with the increased risk of several cancers. The underlying link between obesity, T2D, and cancer is related to insulin resistance, hyperinsulinemia, and disturbances in IGF signaling systems (Figure 1). The insulin resistant state is correlated with a metabolic profile of altered metabolism of protein, which may affect the PFAA profiles. Looking at previous clinical data, the metabolic alterations of insulin resistance, T2D or cancers can determine their own unique PFAA profiles. Although PFAA alterations can be used for diagnosis of cancers or T2D with sufficient sensitivity and robustness, the specificity is low. The discrepancies exist between the results of previous studies due to the variations in participant characteristics, for example, age, gender, ethnic background, degree of obesity, diet, different techniques for amino acids measurement, different types and stages of cancers and limited size of data set.

Future research is needed to investigate the characteristic PFAA profiles to discriminate individual cancer types with different stages from healthy controls. Additional validation of the profiles using a larger sample size is necessary to establish the clinical utility. Furthermore, it is needed to elucidate the biological mechanisms by which amino acids might promote cancer risk and progression or T2D and its complications because the roles of insulin resistance or hyperinsulinemia or hyperglycemia in regulating the enzymes utilizing amino acids are still incompletely understood. Although our understanding of alterations in PFAAs metabolism in the diabetic or cancer states remains immature, we believe that PFAA profiling has the clinical usefulness for the detection of cancers or T2D.

On the other hand, while it is evident that Asian populations are more insulin resistant than other ethnic groups, in spite of less obesity, it is necessary to better identify the factors underlying the interethnic differences. As mentioned earlier, PFAA profiles have been utilized as biomarkers to detect cancers and diabetes. However, few studies have been investigated whether specific populations in Asia may have different PFAA profiles. To our best knowledge, only a few studies have been conducted in Asian populations, most of which are limited to Japanese. The rising prevalence of diabetes and cancers in Asia urgently need to clarify the associations of PFAA profiles with these diseases. These findings may provide new insight into how dietary or other interventions alter PFAA profiling in humans and to access whether these changes could ultimately improve metabolic health in cancer patients or pre-diabetes or T2D patients.


The authors greatly acknowledge the financial support from Singapore Institute for Clinical Sciences, Agency for Science, Technology, and Research (A*Star), Singapore.


  1. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer2009; 16: 1103–1123.19620249
  2. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA et al. Diabetes and cancer: a consensus report. Diabetes Care2010; 33: 1674–1685.20587728
  3. Joh HK, Willett WC, Cho E. Type 2 diabetes and the risk of renal cell cancer in women. Diabetes Care2011; 34: 1552–1556.21602426
  4. Kahn SE, Hull RL, Utzschneider KM. Mechanism linking obesity to insulin resistance and type 2 diabetes. Nature2006; 444: 840–846.17167471
  5. Solarek W, Czarnecka AM, Escudier B, Bielecka ZF, Lian F, Szczylik C. Insulin and IGFs in renal cancer risk and progression. Endocr Relat Cancer2015; 22: R253–R264.26330483
  6. Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev2007; 87: 507–520.17429039
  7. Muoio DM, Newgard CB. Mechanisms of diseases: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol2008; 9: 193–205.18200017
  8. Kim YS, Maruvada P, Milner JA. Metabolomics in biomarker discovery: future uses for cancer prevention. Future Oncol2008; 4: 93–102.18241004
  9. Felig P, Marliss E, Cahill GFJr. Plasma amino acid levels and insulin secretion in obesity. N Engl J Med1969; 281: 811–816.5809519
  10. Costeas PA, Chinsky JM. Effects of insulin on the regulation of branched-chain alpha-keto acid dehydrogenase E1 alpha subunit gene expression. Biochem J1996; 318: 85–92.8761456
  11. Lackey DE, Lynch CJ, Olson KC, Mostaedi R, Ali M, Smith WH et al. Regulation of adipose branched-chain amino acid catabolism enzyme expression and cross-adipose amino acid flux in human obesity. Am J Physiol Endocrinol Metab2013; 304: E1175–E1187.23512805
  12. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab2009; 9: 311–326.19356713
  13. Shah SH, Crosslin DR, Haynes CS, Nelson S, Turer CB, Stevens RD et al. Branched-chain amino acid levels are associated with improvement in insulin resistance with weight loss. Diabetologia2012; 55: 321–330.22065088
  14. McCormack SE, Shaham O, McCarthy MA, Deik AA, Wang TJ, Gerszten RE et al. Circulating branched-chain amino acid concentrations are associated with obesity and future insulin resistance in children and adolescents. Pediatr Obes2013; 8: 52–61.22961720
  15. Wurtz P, Soininen P, Kangas AJ, Rönnemaa T, Lehtimäki T, Kähönen M et al. Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. Diabetes Care2013; 36: 648–655.23129134
  16. Tai ES, Tan MLS, Stevens RD, Low YL, Muehlbauer MJ, Goh DLM et al. Insulin resistance is associated with a metabolic profile of altered protein metabolism in Chinese and Asian-Indian men. Diabetologia2010; 53: 757–767.20076942
  17. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E et al. Metabolite profiles and the risk of developing diabetes. Nat Med2011; 17: 448–453.21423183
  18. Engelen MP, Wouters EF, Deutz NE, Menheere PP, Schols AM. Factors contributing to alterations in skeletal muscle and plasma amino acid profiles in patients with chronic obstructive pulmonary disease. Am J Clin Nutr2000; 72: 1480–1487.11101475
  19. Zhang Q, Takahashi M, Noguchi Y, Sugimoto T, Kimura T, Okumura A et al. Plasma amino acid profiles applied for diagnosis of advanced liver fibrosis in patients with chronic hepatitis C infection. Hepatol Res2006; 34: 170–177.16436332
  20. Fukutake N, Ueno M, Hiraoka N, Shimada K, Shiraishi K, Saruki N et al. A novel multivariate index for pancreatic cancer detection based on the plasma free amino acid profile. PLoS One2015; 10: e0132223.26133769
  21. Yatabe J, Yatabe MS, Ishibashi K, Nozawa Y, Sanada H. Early detection of colon cancer by amino acid profiling using AminoIndex Technology: a case report. Diagn Pathol2013; 8: 203.24325735
  22. Noguchi Y, Zhang QW, Sugimoto T, Furuhata Y, Sakai R, Mori M et al. Network analysis of plasma and tissue amino acids and the generation of an amino index for potential diagnostic use. Am J Clin Nutr2006; 83: 513S–519S.16470023
  23. Huang J, Plass C, Gerheauser C. Cancer chemoprevention by targeting the epigenome. Curr Drug Targets2011; 12: 1925–1956.21158707
  24. Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH et al. Plasma insulin-like growth factor-1, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst2000; 92: 1910–1917.11106682
  25. Burroughs KD, Dunn SE, Barrett JC, Taylor JA. Insulin-like growth factor-1: a key regulator of human cancer risk. J Natl Cancer Inst1999; 91: 579–581.10203270
  26. Proenza AM, Oliver J, Palou A, Roca P. Breast and lung cancer are associated with a decrease in blood cell amino acid content. J Nutr Biochem2003; 14: 133–138.12742540
  27. Vissers YL, Dejong CH, Luiking YC, Fearon KC, Meyenfeldt MF, Deutz NE. Plasma arginine concentrations are reduced in cancer patients: evidence for arginine deficiency? Am J Clin Nutr2005; 81: 1142–1146.15883440
  28. Gu Y, Chen T, Fu S, Sun X, Wang L, Wang J et al. Perioperative dynamics and significance of amino acid profiles in patients with cancer. J Transl Med2015; 13: 35.25622826
  29. Miyagi Y, Higashiyama M, Gochi A, Akaike M, Ishikawa T, Miura T et al. Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS One2011; 6: e24143.21915291
  30. Okamoto N, Miyagi Y, Chiba A, Akaike M, Shiozawa M, Imaizumi A et al. Diagnostic modeling with differences in plasma amino acid profiles between non-cachectic colorectal/breast cancer patients and healthy individuals. Int J Med Med Sci2009; 1: 1–8.
  31. Poschke I, Mao Y, Kiessling R, Boniface J. Tumor-dependent increase of serum amino acid levels in breast cancer patients has diagnostic potential and correlates with molecular tumor subtypes. J Transl Med2013; 11: 290.24237611
  32. Barnes T, Bell K, DiSebastiano KM, Vance V, Hanning R, Russell C et al. Plasma amino acid profiles of breast cancer patients early in the trajectory of the disease differ from healthy comparison groups. Appl Physiol Nutr Metab2014; 39: 740–744.24819038
  33. Nagata C, Wada K, Tsuji M, Hayashi M, Takeda N, Yasuda K. Plasma amino acid profiles are associated with biomarkers of breast cancer risk in premenopausal Japanese women. Cancer Causes Control2014; 25: 143–149.24186145
  34. Shingyoji M, Iizasa T, Higashiyama M, Imamura F, Saruki N, Imaizumi A et al. The significance and robustness of a plasma free amino acid (PFAA) profile-based multiplex function for detecting lung cancer. BMC Cancer2013; 13: 77.23409863
  35. Zhao Q, Cao Y, Wang Y, Hu C, Hu A, Ruan L et al. Plasma and tissue free amino acid profiles and their concentration correlation in patients with lung cancer. Asia Pac J Clin Nutr2014; 23: 429–436.25164454
  36. Kim HJ, Jang SH, Ryu JS, Lee JE, Kim YC, Lee MK et al. The performance of a novel amino acid multivariate index for detecting lung cancer: a case control study in Korea. Lung Cancer2015; 90: 522–527.26476713
  37. Schrader H, Menge BA, Belyaev O, Uhl W, Schmidt WE, Meier JJ. Amino acid malnutrition in patients with chronic pancreatitis and pancreatic carcinoma. Pancreas2009; 38: 416–421.19169171
  38. Kobayashi T, Nishiumi S, Ikeda A, Yoshie T, Sakai A, Matsubara A et al. A novel serum metabolomics-based diagnostic approach to pancreatic cancer. Cancer Epidemiol Biomarkers Prev2013; 22: 571–579.23542803
  39. Ma H, Hasim A, Mamtimin B, Kong B, Zhang HP, Sheyhidin I. Plasma free amino acid profiling of esophageal cancer using high-performance liquid chromatography spectroscopy. World J Gastroenterol2014; 20: 8653–8659.25024622
  40. Zhang J, Bowers J, Liu L, Wei S, Gowda GA, Hammoud Z et al. Esophageal cancer metabolite biomarkers detected by LC-MS and NMR methods. PLoS One2012; 7: e30181.22291914
  41. Leichtle AB, Nuoffer JM, Ceglarek U, Kase J, Conrad T, Witzigmann H et al. Serum amino acid profiles and their alterations in colorectal cancer. Metabolomics2012; 8: 643–653.22833708
  42. Hasim A, Aili A, Maimaiti A, Mamtimin B, Abudula A, Upur H. Plasma-free amino acid profiling of cervical cancer and cervical intraepithelial neoplasia patients and its application for early detection. Mol Biol Rep2013; 40: 5853–5859.24068431
  43. Ihata Y, Miyagi E, Numazaki R, Muramatsu T, Imaizumi A, Yamamoto H et al. Amino acid profile index for early detection of endometrial cancer: verification as a novel diagnostic marker. Int J Clin Oncol2014; 19: 364–372.23700142
  44. Buijs N, van Bokhorst-de van der Schueren MA, Langius JA, Leemans CR, Kuik DJ, Vermeulen MA et al. Perioperative arginine-supplemented nutrition in malnourished patients with head and neck cancer improves long-term survival. Am J Clin Nutr2010; 92: 1151–1156.20881073
  45. Maeda J, Higashiyama M, Imaizumi A, Nakayama T, Yamamoto H, Daimon T et al. Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study. BMC Cancer2010; 10: 690.21176209
  46. Okamoto N. Use of 'AminoIndex Technology' for cancer screening. Ningen Dock2012; 26: 911–922.
  47. Medina MA, Marquez J, Nunez de Castro I. Interchange of amino acids between tumor and host. Biochem Med Metab Biol1992; 48: 1–7.1524866
  48. Marquez J, Sanchez-Jimenez F, Medina MA, Quesada AR, Nunez de Castro I. Nitrogen metabolism in tumor bearing mice. Arch Biochem Biophys1989; 268: 667–675.2913952
  49. Cascino A, Muscaritoli M, Cangiano C, Coversano L, Laviano A, Ariemma S et al. Plasma amino acid imbalance in patients with lung and breast cancer. Anticancer Res1995; 15: 507–510.7763031
  50. Medina MA. Glutamine and cancer. J Nutr2001; 131: 2539S–2542S.11533309
  51. Chen L, Cui H. Targeting glutamine induces apoptosis: a cancer therapy approach. Int J Mol Sci2015; 16: 22830–22855.26402672
  52. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol1927; 8: 519–530.19872213
  53. Korangath P, Teo WW, Sadik H, Han L, Mori N, Huijts CM et al. Targeting glutamine metabolism in breast cancer with aminooxyacetate. Clin Cancer Res2015; 21: 3263–3273.25813021
  54. Cheng T, Sudderth J, Yang C, Mullen AR, Jin ES, Mates JM et al. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc Natl Acad Sci USA2011; 108: 8674–8679.21555572
  55. Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, Souza AL et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science2012; 336: 1040–1044.22628656
  56. Amelio I, Cutruzzola F, Antonov A, Agostini M, Melino G. Serine and glycine metabolism in cancer. Trends Biochem Sci2014; 39: 191–198.24657017
  57. Zhang WC, Shyh-Chang N, Yang H, Rai A, Umashankar S, Ma S et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell2012; 148: 259–272.22225612
  58. Kim SK, Jung WH, Koo JS. Differential expression of enzymes associated with serine/glycine metabolism in different breast cancer subtypes. PLoS One2014; 9: 101004.
  59. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature2011; 476: 346–350.21760589
  60. Labuschagne CF, van den Broek NJ, Mackay GM, Vousden KH, Maddocks OD. Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells. Cell Rep2014; 7: 1248–1258.24813884
  61. Mayers JR, Wu C, Clish CB, Kraft P, Torrence ME, Fiske BP et al. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med2014; 20: 1193–1198.25261994
  62. Sugiyama K, Yu L, Nagasue N. Direct effect of branched-chain amino acids on the growth and metabolism of cultured human hepatocellular carcinoma cells. Nutr Cancer1998; 31: 62–68.9682250
  63. Iwasa J, Shimizu M, Shiraki M, Shirakami Y, Sakai H, Terakura Y et al. Dietary supplementation with branched-chain amino acids suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice. Cancer Sci2010; 101: 460–467.19906067
  64. Formisano P, Oriente F, Fiory F, Caruso M, Miele C, Maitan MA et al. Insulin-activated protein kinase Cbeta bypasses Ras and stimulates mitogen-activated protein kinase activity and cell proliferation in muscle cells. Mol Cell Biol2000; 20: 6323–6333.10938109
  65. Miuma S, Ichikawa T, Arima K, Takeshita S, Muraoka T, Matsuzaki T et al. Branched-chain amino acid deficiency stabilizes insulin-induced vascular endothelial growth factor mRNA in hepatocellular carcinoma cells. J Cell Biochem2012; 113: 3113–3121.22581719
  66. Hagiwara A, Nishiyama M, Ishizaki S. Branched-chain amino acids prevent insulin-induced hepatic tumor cell proliferation by inducing apoptosis through mTORC1 and mTORC2-dependent mechanisms. J Cell Physiol2012; 227: 2097–2105.21769869
  67. Kim T, Kim AK. Taurine enhances anticancer activity of cisplatin in human cervical cancer cells. Adv Exp Med Biol2013; 776: 189–198.23392883
  68. Agouza EI, Eissa IM, SS, Houseini EI, EI-Nashar MM, Abd DE et al. A novel tumor marker for enhanced detection of breast cancer amnong female patients. Angiogenesis2011; 14: 321–330.21553281
  69. Lind DS. Arginine and cancer. J Nutr2004; 134: 2837S–2841S.15465796
  70. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care2004; 27: 1047–1053.15111519
  71. Peters AL, Davidson MB, Schriger DL, Hasselblad V. A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. Meta-analysis research group on the diagnosis of diabetes using glycated hemoglobin levels. JAMA1996; 276: 1246–1252.8849753
  72. Adams SH. Emerging perspectives on essential amino acid metabolism in obesity and the insulin-resistant state. Adv Nutr2011; 2: 445–456.22332087
  73. Fiehn O, Garvey WT, Newman JW, Lok KH, Hoppel CL, Adams SH. Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women. PLoS ONE2010; 5: e15234.21170321
  74. Nilsson M, Holst JJ, Bjorck IM. Metabolic effects of amino acid mixtures and whey protein in healthy subjects: studies using glucose-equivalent drinks. Am J Clin Nutr2007; 85: 996–1004.17413098
  75. Van Loon LJ, Saris WH, Verhagen H, Wagenmakers AJ. Plasma insulin responses after ingestion of different amino acid or protein mixtures with carbohydrate. Am J Clin Nutr2000; 72: 96–105.10871567
  76. Buse MG, Biggers JF, Friderici KH, Buse JF. Oxidation of branched chain amino acids by isolated hearts and diaphragms of the rat. The effect of fatty acids, glucose, and pyruvate respiration. J Biol Chem1972; 247: 8085–8096.4640937
  77. Wang TJ, Larson MG, Vasan RS, Cheng S, Phee EP, McCabe E et al. Metabolite profiles and the risk of developing diabetes. Nat Med2011; 17: 448–454.21423183
  78. Magnusson M, Lewis GD, Ericson U, Orho-Melander M, Hedblad B, Engstrom G et al. A diabetes-predictive amino acid score and future cardiovascular disease. Eur Heart J2013; 34: 1982–1989.23242195
  79. Wurtz P, Makinen VP, Soininen P, Kangas AJ, Tukiainen T, Kettunen J et al. Metabolic signatures of insulin resistance in 7098 young adults. Diabetes2012; 61: 1372–1380.22511205
  80. Yamada C, Kondo M, Kishimoto N, Shibata T, Nagai Y, Imanishi T et al. Association between insulin resistance and plasma amino acid profile in non-diabetic Japanese subjects. J Diabetes Invest2015; 6: 408–415.
  81. Nakamura H, Jinzu H, Nagao K, Noguchi Y, Shimba N, Miyano H et al. Plasma amino acid profiles are associated with insulin, C-peptide and adiponectin levels in type 2 diabetic patients. Nutr Diabetes2014; 4: e133.25177913
  82. Martin FPJ, Montoliu I, Collino S, Scherer M, Guy P, Tavazzi I et al. Topographical body fat distribution links to amino acid and lipid metabolism in healthy non-obese women. PLoS One2013; 8: e73445.24039943
  83. Yamakado M, Tanaka T, Nagao K, Ishizaka Y, Mitushima T, Tani M et al. Plasma amino acid profile is associated with visceral fat accumulation in obese Japanese subjects. Clin Obes2012; 2: 29–40.25586045
  84. Wang-Sattler R, Yu Z, Herder C, Messias AC, Floegel A, He Y et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol2012; 8: 615.23010998
  85. Floegel A, Stefan N, Yu Z, Muhlenbruch K, Drogan D, Joost HG et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes2013; 62: 639–648.23043162
  86. Kume S, Araki S, Ono N, Shinhara A, Muramatsu T, Araki H et al. Predictive properties of plasma amino acid profile for cardiovascular disease in patients with type 2 diabetes. PLoS One2015; 9: e101219.
  87. Yamakado M, Nagao K, Imaizumi A, Tani M, Toda A, Tanaka T et al. Plasma free amino acid profiles predict four-year risk of developing diabetes, metabolic syndrome, dyslipidemia, and hypertension in Japanese population. Sci Rep2015; 5: 11918.26156880
  88. Wurtz P, Tiainen M, Makinen VP, Kangas AJ, Soininen P, Saltevo J et al. Circulating metabolite predictors of glycemia in middle-aged men and women. Diabetes Care2012; 35: 1749–1756.22563043
  89. Huffman KM, Shah SH, Stevens RD, Bain JR, Muehlbauer M, Slentz CA et al. Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. Diabetes Care2009; 32: 1678–1683.19502541
  90. Sekhar RV, McKay SV, Patel SG, Guthikonda AP, Reddy VT, Balasubramanyam A et al. Glutathione synthesis is diminished in patients with uncontrolled diabetes and restored by dietary supplementation with cysteine and glycine. Diabetes Care2011; 34: 162–167.20929994
The underlying source XML for this text is taken from The license for the article is Creative Commons Attribution 4.0 International. The main subject has been identified as maturity-onset diabetes of the young.